BRPI1009663A2 - "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica" - Google Patents
"método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"Info
- Publication number
- BRPI1009663A2 BRPI1009663A2 BRPI1009663A BRPI1009663A BRPI1009663A2 BR PI1009663 A2 BRPI1009663 A2 BR PI1009663A2 BR PI1009663 A BRPI1009663 A BR PI1009663A BR PI1009663 A BRPI1009663 A BR PI1009663A BR PI1009663 A2 BRPI1009663 A2 BR PI1009663A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- requirement
- need
- pharmaceutical composition
- platelet levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18685709P | 2009-06-14 | 2009-06-14 | |
PCT/IL2010/000466 WO2010146578A2 (en) | 2009-06-14 | 2010-06-13 | Peptide therapy for increasing platelet levels |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1009663A2 true BRPI1009663A2 (pt) | 2016-10-11 |
Family
ID=43356827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1009663A BRPI1009663A2 (pt) | 2009-06-14 | 2010-06-13 | "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica" |
Country Status (11)
Country | Link |
---|---|
US (1) | US9427456B2 (pt) |
EP (1) | EP2442822B1 (pt) |
JP (1) | JP5715622B2 (pt) |
KR (1) | KR101719339B1 (pt) |
CN (1) | CN102481332A (pt) |
BR (1) | BRPI1009663A2 (pt) |
CA (1) | CA2765345C (pt) |
ES (1) | ES2462517T3 (pt) |
IL (1) | IL216912A (pt) |
MX (1) | MX2011013459A (pt) |
WO (1) | WO2010146578A2 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
EP1541585B1 (en) | 2002-08-27 | 2013-01-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist and use thereof |
EP3011961B1 (en) * | 2006-12-21 | 2020-11-11 | Biokine Therapeutics LTD. | 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation |
WO2010146578A2 (en) | 2009-06-14 | 2010-12-23 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
EP2663320A1 (en) | 2011-01-10 | 2013-11-20 | Biokine Therapeutics Ltd. | Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
JP2015154715A (ja) * | 2012-05-22 | 2015-08-27 | 国立大学法人旭川医科大学 | ヒト単核球由来の新規血管再生細胞群及びその分化誘導法 |
WO2014089478A1 (en) * | 2012-12-07 | 2014-06-12 | University Of Tennessee Research Foundation | Methods of numerical analysis for platelet disorders and computer-readable media and systems for performing the same |
CN106535887A (zh) * | 2014-05-15 | 2017-03-22 | 株式会社Enzychem生命科学 | 治疗白细胞减少症和血小板减少症的方法 |
JP6547274B2 (ja) | 2014-10-20 | 2019-07-24 | 株式会社デンソー | 粒子状物質検出センサ |
KR20210089270A (ko) | 2015-07-16 | 2021-07-15 | 바이오카인 테라퓨틱스 리미티드 | 암 치료용 조성물 및 방법 |
BR112018016924A2 (pt) | 2016-02-23 | 2019-01-02 | Biokine Therapeutics Ltd | método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma |
US11273203B2 (en) * | 2019-01-25 | 2022-03-15 | Janssen Pharmaceutica Nv | Methods of mitigating toxic effects of vesicants and caustic gas |
JP2023517616A (ja) * | 2020-03-11 | 2023-04-26 | バイオラインアールエックス・リミテッド | 急性呼吸窮迫症候群およびウイルス感染の治療用のcxcr4阻害剤 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
JPS61227526A (ja) | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
EP0215126B1 (en) | 1985-02-08 | 1991-07-31 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
EP1186663A1 (en) | 1985-08-23 | 2002-03-13 | Kirin-Amgen, Inc. | Production of pluripotent granulocyte colony-stimulating factor |
ATE67517T1 (de) | 1985-09-30 | 1991-10-15 | Chugai Pharmaceutical Co Ltd | Menschlicher granulozyten-colony stimulierender faktor. |
JPH0618778B2 (ja) | 1985-10-04 | 1994-03-16 | 中外製薬株式会社 | 白血球減少症治療剤 |
DE3777845D1 (de) | 1986-01-22 | 1992-05-07 | Chugai Pharmaceutical Co Ltd | Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie. |
DE3771509D1 (de) | 1986-01-22 | 1991-08-29 | Chugai Pharmaceutical Co Ltd | Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. |
DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
JPH0725689B2 (ja) | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
DK174044B1 (da) | 1986-12-23 | 2002-05-06 | Kyowa Hakko Kogyo Kk | Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid....... |
JP2618618B2 (ja) | 1988-03-04 | 1997-06-11 | 協和醗酵工業株式会社 | 抗g−csf誘導体、nd28モノクローナル抗体 |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
DE68918331T2 (de) | 1988-06-03 | 1995-05-18 | Chugai Pharmaceutical Co Ltd | Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung. |
CA1339071C (en) | 1988-08-24 | 1997-07-29 | Koichiro Tsuji | Thrombus control agent |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5104651A (en) | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
IL96477A0 (en) | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
JP3249147B2 (ja) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
EP0459516A1 (en) | 1990-06-01 | 1991-12-04 | Kirin-Amgen, Inc. | Oral dosage form of biologically active proteins |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
FR2686900B1 (fr) | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
US5776899A (en) | 1993-10-14 | 1998-07-07 | Seikagaku Corporation | Polypeptide and anti-HIV agent prepared therefrom |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5492126A (en) | 1994-05-02 | 1996-02-20 | Focal Surgery | Probe for medical imaging and therapy using ultrasound |
AU7589898A (en) | 1997-05-21 | 1998-12-11 | Genentech Inc. | Novel administration of thrombopoietin |
US6128522A (en) | 1997-05-23 | 2000-10-03 | Transurgical, Inc. | MRI-guided therapeutic unit and methods |
US6569418B1 (en) | 1997-12-11 | 2003-05-27 | University Of Maryland Biotechnology Institute | Immuno-modulating effects of chemokines in DNA vaccination |
WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
WO1999047158A2 (en) | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
CA2305787A1 (en) | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
CA2245224A1 (en) | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
AU5241099A (en) | 1998-07-31 | 2000-02-21 | Trustees Of Columbia University In The City Of New York, The | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
EA003634B1 (ru) | 1998-10-05 | 2003-08-28 | Фармэкса А/С | Новые способы терапевтической вакцинации |
WO2000024468A1 (de) | 1998-10-27 | 2000-05-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren und vorrichtung zur regelung einer gezielten wärmedeponierung in ein material |
US20060079492A1 (en) * | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
ATE442151T1 (de) | 1999-03-29 | 2009-09-15 | Shire Canada Inc | Verwendung von cytidinderivaten zur behandlung von leukämie |
AU1488501A (en) | 1999-11-24 | 2001-06-04 | Schering Corporation | Methods of inhibiting metastasis |
WO2001064716A1 (fr) | 2000-03-03 | 2001-09-07 | Nobutaka Fujii | Composes antiviraux |
AU5811001A (en) * | 2000-05-09 | 2001-11-20 | Univ British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
CA2421183C (en) | 2000-09-05 | 2015-06-16 | Seikagaku Corporation | Novel polypeptide and anti-hiv agent containing the same |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US7630750B2 (en) | 2001-02-05 | 2009-12-08 | The Research Foundation For The State University Of New York | Computer aided treatment planning |
JP3374917B2 (ja) | 2001-02-16 | 2003-02-10 | サンケン電気株式会社 | スイッチング電源装置 |
US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
US20030221931A1 (en) | 2002-02-28 | 2003-12-04 | Steve Marsh | Sliding device |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
EP1541585B1 (en) | 2002-08-27 | 2013-01-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist and use thereof |
DE10240064A1 (de) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
JP4666256B2 (ja) | 2002-12-10 | 2011-04-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
WO2004087068A2 (en) | 2003-03-27 | 2004-10-14 | Emory University | Cxcr4 antagonists and methods of their use |
EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
US8545463B2 (en) | 2003-05-20 | 2013-10-01 | Optimyst Systems Inc. | Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device |
AU2005224209B2 (en) | 2004-03-19 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Medicine for cancer therapy |
EP1796716A4 (en) | 2004-08-13 | 2010-09-08 | Anormed Inc | COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS |
WO2006082588A2 (en) | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
CN101365336B (zh) | 2005-08-19 | 2013-05-29 | 健赞股份有限公司 | 增强化疗的方法 |
CN101573441A (zh) | 2005-12-08 | 2009-11-04 | 路易斯维尔大学研究基金会有限公司 | 非常小的胚胎样(vsel)干细胞及分离和利用其的方法 |
WO2007146432A2 (en) | 2006-06-15 | 2007-12-21 | Neostem, Inc. | Processing procedure for peripheral blood stem cells |
BRPI0714799A2 (pt) | 2006-08-02 | 2013-05-21 | Genzyme Corp | terapia de combinaÇço |
EP2058395A4 (en) | 2006-08-04 | 2009-12-09 | Univ Kurume | PEPTIDE DERIVED FROM KIF CAPABLE OF BINDING TO A HLA-A24 MOLECULE |
EP3011961B1 (en) | 2006-12-21 | 2020-11-11 | Biokine Therapeutics LTD. | 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation |
WO2010146578A2 (en) | 2009-06-14 | 2010-12-23 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
EP2443137B1 (en) | 2009-06-15 | 2015-05-20 | Biokine Therapeutics Ltd. | Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer |
US20120082687A1 (en) | 2010-10-04 | 2012-04-05 | Alex Wah Hin Yeung | Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use |
EP2663320A1 (en) | 2011-01-10 | 2013-11-20 | Biokine Therapeutics Ltd. | Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
AU2014240733B2 (en) | 2013-03-24 | 2018-11-22 | Biolinerx Ltd. | Methods of treating myeloid leukemia |
CA2920377A1 (en) | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
US20160243187A1 (en) | 2013-10-31 | 2016-08-25 | Biokine Therapeutics Ltd. | Methods of treating acute myeloid leukemia with a flt3 mutation |
-
2010
- 2010-06-13 WO PCT/IL2010/000466 patent/WO2010146578A2/en active Application Filing
- 2010-06-13 ES ES10789103.8T patent/ES2462517T3/es active Active
- 2010-06-13 CN CN2010800359315A patent/CN102481332A/zh active Pending
- 2010-06-13 KR KR1020127000921A patent/KR101719339B1/ko active IP Right Grant
- 2010-06-13 MX MX2011013459A patent/MX2011013459A/es active IP Right Grant
- 2010-06-13 CA CA2765345A patent/CA2765345C/en active Active
- 2010-06-13 US US13/378,061 patent/US9427456B2/en active Active
- 2010-06-13 EP EP10789103.8A patent/EP2442822B1/en active Active
- 2010-06-13 BR BRPI1009663A patent/BRPI1009663A2/pt not_active Application Discontinuation
- 2010-06-13 JP JP2012515626A patent/JP5715622B2/ja active Active
-
2011
- 2011-12-12 IL IL216912A patent/IL216912A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2442822B1 (en) | 2014-03-05 |
IL216912A0 (en) | 2012-02-29 |
WO2010146578A2 (en) | 2010-12-23 |
US9427456B2 (en) | 2016-08-30 |
JP5715622B2 (ja) | 2015-05-07 |
EP2442822A2 (en) | 2012-04-25 |
CA2765345C (en) | 2016-06-21 |
JP2012530130A (ja) | 2012-11-29 |
CN102481332A (zh) | 2012-05-30 |
US20120094907A1 (en) | 2012-04-19 |
KR101719339B1 (ko) | 2017-03-23 |
CA2765345A1 (en) | 2010-12-23 |
MX2011013459A (es) | 2012-05-08 |
KR20120037463A (ko) | 2012-04-19 |
IL216912A (en) | 2015-09-24 |
EP2442822A4 (en) | 2013-01-23 |
WO2010146578A3 (en) | 2011-02-10 |
ES2462517T3 (es) | 2014-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1009663A2 (pt) | "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica" | |
BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
BR112012015540A2 (pt) | composto, uso de composto, método para tratar um individuo, método de inibir janus quinases em um individuo, composição farmacêutica e combinação de produto | |
BRPI0815170A2 (pt) | Composição farmacêutica que compreende um inibidor de sglt 2 | |
BRPI0909780A2 (pt) | Composições e métodos para liberação de fármaco | |
BRPI0914406A2 (pt) | composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero | |
BRPI0909436A2 (pt) | dsitribuidor de turbina para uma turbomáquina, turbina de turbomáquina e turbomáquina | |
BRPI0905912A2 (pt) | "métodos para a detecção de um microorganismo alvo e composição para detecção de microorganismo alvo" | |
ES2965209T3 (es) | Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina | |
BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
BRPI0910406A2 (pt) | equipamento e métodos para otmimização de tranporte para entrega de conteúdo widget | |
BRPI0821680A2 (pt) | Sistema e método para recomendações alvo que usam rede de jogos sociais | |
BRPI0809655A2 (pt) | Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit | |
BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
BRPI1013002A2 (pt) | sistemas e métodos para entrega de conteúdo | |
BRPI0909183A2 (pt) | Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase | |
BR112013015010A2 (pt) | produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana | |
BRPI0911681A2 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula | |
BRPI0821876A8 (pt) | sistemas e métodos para administração de medicação | |
BRPI0807918A2 (pt) | composições e método para preservação de tecido | |
BRPI0820253A2 (pt) | Sistema de sensoriamento, e, método para sensoriar uma mudança em uma propriedade de um material | |
BRPI1014824A2 (pt) | composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo | |
BRPI1014865A2 (pt) | "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica" | |
BRPI1006145A2 (pt) | "composição e método para tratamento de diabetes". |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |